Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Jasper Therapeutics Inc. (NQ: JSPR )

25.02 +0.68 (+2.79%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 72,416
Open 24.40
Bid (Size) 24.55 (1)
Ask (Size) 25.30 (8)
Prev. Close 24.34
Today's Range 23.90 - 25.25
52wk Range 0.4000 - 31.01
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
JSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q1 2024
JSPR stock results show that Jasper Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Spirit Airlines Posts Weak Results, Joins Integra LifeSciences, Bowlero And Other Big Stocks Moving Lower On Monday
Via Benzinga

Performance

YTD
+3576.17%
+3576.17%
1 Month
+9.52%
+9.52%
3 Month
+0.64%
+0.64%
6 Month
+5339.13%
+5339.13%
1 Year
+1713.04%
+1713.04%

More News

Read More
JSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q4 2023
Via InvestorPlace
Over $15M Bet On Aon? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Why FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Jasper Therapeutics: Q3 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Jasper Therapeutics, Inc.
Via GlobeNewswire
Where Jasper Therapeutics Stands With Analysts
Via Benzinga
Jasper Therapeutics: Q1 Earnings Insights
Via Benzinga
7 Analysts Have This to Say About Jasper Therapeutics
Via Benzinga
Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Jasper Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
From Jasper Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2023
Via Benzinga
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus
Via MarketBeat
Topics Retirement
Exposures Pension
Jasper Therapeutics, Inc. (NASDAQ: JSPR) Featured in Coverage of the Inaugural EF Hutton Global Conference
Via Investor Brand Network
$4M Bet On Jasper Therapeutics? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
Why iMedia Brands Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Jasper Therapeutics Touts Encouraging Data From Briquilimab Conditioning In Inherited Bone Marrow Disorder
Via Benzinga
Why Nogin Shares Are Trading Higher By Around 77%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.